| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Debt extinguishment costs | NaN | 0 | 0 | -1,269 |
| Legal settlements expense | NaN | NaN | 0 | 3,504 |
| Non-cash legal settlements expense | NaN | 3,504 | NaN | NaN |
| Net income | 4,464 | -1,177,240 | 38,317 | 47,000 |
| Loss on impairment | NaN | 1,006,440 | 0 | 1,452 |
| Depreciation and amortization | 52,426 | 45,754 | 47,468 | 96,027 |
| Amortization of debt issuance costs | 1,253 | 1,351 | 1,235 | 2,278 |
| Equity-based compensation expense | 7,956 | 6,451 | 6,031 | 19,226 |
| Deferred income taxes | 10,340 | -2,215 | 12,062 | -8,753 |
| Gain on sale of property, net | 1,222 | 0 | 0 | 8,715 |
| Other | -401 | 284 | -779 | -1,128 |
| Accounts receivable, net | 31,148 | 10,066 | 22,298 | 42,660 |
| Other current assets | -27,501 | 29,619 | 13,793 | 3,797 |
| Other assets | 542 | 426 | 3,181 | 7,684 |
| Accounts payable and other accrued liabilities | 24,402 | -18,702 | 5,900 | 27,684 |
| Accrued salaries and benefits | -34,570 | 21,520 | 9,098 | -3,940 |
| Other liabilities | 270 | 70,743 | -8,408 | 20,962 |
| Net cash provided by operating activities | 61,531 | -86,293 | 73,210 | 144,981 |
| Cash paid for acquisitions, net of cash acquired | NaN | 0 | 0 | 8,165 |
| Cash paid for capital expenditures | 76,564 | 93,190 | 136,239 | 342,378 |
| Proceeds from sale of property and equipment | 16,383 | 697 | 6,528 | 16,623 |
| Other | 30 | -55 | 44 | 101 |
| Net cash used in investing activities | -60,211 | -92,438 | -129,755 | -334,021 |
| Borrowings on long-term debt | NaN | 0 | 0 | 1,200,000 |
| Distributions to noncontrolling partners in joint ventures | NaN | 0 | 1,887 | 1,990 |
| Repayment of long-term debt | NaN | 0 | 0 | 670,856 |
| Payment of debt issuance costs | NaN | 0 | 0 | 18,615 |
| Borrowings on revolving credit facility | 85,000 | 194,000 | 45,000 | 830,000 |
| Repurchase of common stock | NaN | 0 | 0 | 50,034 |
| Principal payments on revolving credit facility | 55,000 | 0 | 0 | 1,035,000 |
| Cash paid for contingent consideration | NaN | 0 | 0 | 1,500 |
| Principal payments on long-term debt | 4,063 | 4,063 | 4,062 | 4,063 |
| Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises | -2,744 | -273 | -237 | -3,716 |
| Contributions from noncontrolling partners in joint ventures | 743 | 3,639 | 5,000 | NaN |
| Other | -26 | -23 | 3 | -70 |
| Net cash provided by financing activities | 23,910 | 193,280 | 43,817 | 244,156 |
| Net increase in cash and cash equivalents | 25,230 | 14,549 | -12,728 | 55,116 |
| Cash and cash equivalents at beginning of the period | 133,242 | 118,693 | 76,305 | NaN |
| Cash and cash equivalents at end of the period | 158,472 | 133,242 | 118,693 | NaN |
Acadia Healthcare Company, Inc. (ACHC)
Acadia Healthcare Company, Inc. (ACHC)